Clinical Evidence: How Probiotic IDCC 1201 Modulates the Gut Microbiome and Metabolome
Understanding the relationship between gut microbiota and microbial metabolites is essential for developing next-generation probiotics. A recent clinical study published in Nutrients (2026) investigated the effects of Heyndrickxia coagulans IDCC 1201 (formerly Bacillus coagulans) on gastrointestinal symptoms, gut microbiome composition, and fecal metabolomic profiles in adults with functional bowel disorders (FBDs).
In this randomized, double-blind, placebo-controlled trial, participants received at least 5 billion CFU of IDCC 1201 daily for eight weeks. Clinical outcomes were assessed using IBS Symptom Severity Score (IBS-SSS), IBS Quality of Life (IBS-QOL), and bowel activity questionnaires.
The results demonstrated improvements in abdominal bloating and post-defecation discomfort, alongside a significant improvement in the body image domain of IBS-QOL compared with placebo.
Microbiome analysis using 16S rRNA gene sequencing revealed selective enrichment of beneficial microbial taxa, including Ruminococcus bromii, Agathobacter rectalis, and Bifidobacterium. Notably, these changes occurred without significant alterations in overall alpha or beta diversity, suggesting targeted microbiota modulation rather than broad changes in microbial diversity.
Furthermore, GC-MS-based untargeted metabolomic profiling identified distinct metabolic signatures following IDCC 1201 supplementation. Significant longitudinal changes included increased alanine and proline levels, while treatment-associated metabolic differences involved tryptophan, lactic acid, and phytosphingosine.
These findings provide clinical insights into the interaction between probiotic supplementation, gut microbial composition, and metabolic activity.
At ILDONG Bioscience, we continue to advance strain-specific probiotic research by integrating clinical evaluation with microbiome and metabolomic analyses. This research reinforces our commitment to developing scientifically validated probiotic ingredients for global digestive health applications.
Reference: Jeon et al. (2026). Heyndrickxia coagulans IDCC 1201 Alters Gut Microbiome and Metabolome in Patients with Functional Bowel Disorders. Nutrients, 18(15), 2466.
